AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06544876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stand to sit
Description: test for balance during movement from standing to sitting
Study NCT06544876 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standing perturbation
Description: test for balance recovery following perturbation
Study NCT06544876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standing perturbation
Description: test for balance recovery following perturbation
Study NCT06544876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI of sciatic nerve
Description: measure of peripheral nerve diameter
Study NCT06544876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI of sciatic nerve
Description: measure of peripheral nerve diameter
Study NCT05679765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Greater Occipital Nerve Block with dexamethasone and lidocaine
Description: Ultrasound guided Greater occipital nerve block on the side of headache
Study NCT05679765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Greater Occipital Nerve Block with dexamethasone and lidocaine
Description: Ultrasound guided Greater occipital nerve block on the side of headache
Study NCT05679765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Greater Occipital Nerve Block with 0.9% saline
Description: Ultrasound guided Greater occipital nerve block on the side of headache
Study NCT05679765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Greater Occipital Nerve Block with 0.9% saline
Description: Ultrasound guided Greater occipital nerve block on the side of headache
Study NCT05908747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib + gemcitabine + nab-paclitaxel
Description: surufatinib: 250mg, QD po; nab-paclitaxel: 125mg/m2, I.V., D1/8/15, Q4W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1/8/15, Q4W
Study NCT05775926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Nursing Care and Challenges Training for Nurses Caring for Dying Cancer Patients and Their Families was given in 4 modules and 2 days.
Study NCT06035939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice Crisis Alert V2
Description: The mHealth self-management intervention consists of the following components: 1) condition-specific electronic educational materials; 2) pain/symptom monitoring and tracking; 3) health history information documentation; 4) medication tracking; 5) secure messaging with a provider; 6) functioning monitoring and tracking; and 7) transmission of health information (graphs with recorded pain and functioning histories) to a provider.
Study NCT06035939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic educational materials
Description: The control arm will receive enhanced usual care, which will consist of usual educational materials distributed at the clinic plus a version of the intervention (Voice Crisis Alert V2) that only includes the electronic educational materials.
Study NCT05760300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bulevirtide (BLV)
Description: Administered via subcutaneous (SC) injections
Study NCT05641662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Farming
Description: Heart Farming is a mobile game. which can be played indoors and outdoors and stimulates players to be physically active. The game is built around a theme (farming) and users are challenged to collect products by being active. The phone will register movements and convert them into points and fruits and vegetables. For the basic playing only 10 minutes walking a day with the game is possible and is rewarded. For players who want more challenge and level of trading products and collecting products in groups is added. The game is adaptable to different levels of mobility and players can invite others to play with them. Players can see their own game results, progression, and active time.
Study NCT05212480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Zinc
Description: For each patient included, a prescription regimen of zinc (in bisglycinate form) is proposed at a dose of 25 mgtwice a day for 15 days for the intervention arm. This dose of zinc is to be taken away from meals.
Study NCT05212480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For each patient included, a prescription of an identical to the intervention arm concerning shape, smell, taste and color pill of placebo . This dose of zinc is to be taken away from meals.
Study NCT05477628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Childcare Navigator
Description: Participants will be contacted by the CN to assist with access to centre-based childcare after enrolment. The CN will: a) educate the family on the benefits of centre based childcare; b) facilitate placement of the child on waiting lists for funding and centre based childcare placement in their neighbourhood with the aim of having full-time centre based childcare start at 1 year of age; and c) work with the family to overcome barriers to childcare placement prior to and during childcare. It is expected that the child will be in full-time centre-based childcare for a minimum of 12 months.~Control: All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare according to the Rourke Baby Record.
Study NCT05477628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactation Consultant
Description: Participants will be contacted by the LC on the same day as their first primary healthcare visit. They will also receive age-appropriate nutrition recommendations according to the Rourke Baby Record. The LC will be an International Board Certified Lactation Consultant (IBCLC) who will provide scheduled and on-call visits, along with phone calls, video conferencing, and text messaging as needed to support exclusive breastfeeding (using virtual care modalities as appropriate during COVID-19). The LC will contact the family once per week for the first 4 weeks to support breastfeeding technique and help with breastfeeding problems such as latching difficulties, painful nursing, and low milk production, monthly thereafter and provide on-call support as required to support exclusive breastfeeding through 6 months of age.~Control: All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare.
Study NCT05477628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactation Consultant Support and Childcare Navigator Support
Description: This intervention is a combination of the two interventions described above.
Study NCT05477628 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare.
Study NCT06174818 — intervention group
Intervention type: PROCEDURE
Intervention: PRF
Description: Pulsed Radiofrequency Current of the Gasserian Ganglion
Study NCT05415241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: Stage 1 (Exploring the dose): Twenty participants will be enrolled for aerosol inhalation of FB2001 once daily for 5 consecutive days. If the drug is well tolerated but efficacy is inadequate, another twenty participants will be enrolled for aerosol inhalation of FB2001 BID for 5 consecutive days.~Stage 2 (Sample size expansion): Another twenty participants will be enrolled for aerosol inhalation of FB2001 once daily or twice daily for 5 consecutive days depending on the result of stage 1.
Study NCT05262166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INTRATHECAL dexmedetomidine INJECTION
Description: intrathecal bolus of 3ml bupivacaine 0.5% (15mg) plus 10 micrograms dexmedetomidine at 2-3 or 3-4 spinal level.
Study NCT05775861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single shot interscalene brachial plexus block group with dexmedetomidine added to ropivacaine group
Description: For the single shot group with dexmedetomidine added to ropivacaine group (Group D), after local analgesia with 3 mL of 1% lidocaine, the block will be performed under ultrasound guidance using an in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany).~The perineural solution will be pre-mixed in a 30 mL syringe before the realization of the block.~A total of 150 mg of ropivacaine 0.5% will be prepared, 125 mg (25mL) will be mixed with a dose of 2 mcg/kg IBW of dexmedetomidine (100 mcg/mL dexmedetomidine hydrochloride; Precedex, Hospira Inc, Lake Forest, IL). The total of 25 mL (125 mg or ropivacaine 0.5%) with dexmedetomidine will be injected perineurally at the level of the roots and a 5 mL (25 mg) will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block.
Study NCT05775861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous interscalene brachial plexus block
Description: The block will be performed under ultrasound guidance using an in-plane approach with a 17G Tuohy needle (Arrow FlexBlock). A total of 100 mg (20 mL) of ropivacaine 0,5% will be injected perineurally at the level of the roots using the Tuohy needle. The 19 G arrow catheter will then be introduced through the Tuohy needle and we will leave 4 cm of the catheter perineurally. An additional 25 mg (5 mL) of ropivacaine 0,5% will be injected using the catheter to make sure the catheter is in a correct position. An additional 5 mL (25 mg) of ropivacaine 0.5 % will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block using an ultrasound in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany) or with a standard 25G 1 1/2 inches needle. After the surgery, an infusion of ropivacaine 0,2% at a standard rate of 5 mL/h will be started using an elastomeric pump of 300 mL (Baxter Corporation, Mississauga, Ontario).
Study NCT05762536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide 600 mg b.i.d. until the end of the last taxane cycle
Study NCT05762536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel or cabazitaxel
Description: Docetaxel or cabazitaxel Q3W
Study NCT05762536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel or cabazitaxel
Description: Docetaxel or cabazitaxel Q3W
Study NCT05078684 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left ganglion stellate block
Description: Ultrasound-guided anesthetic block of left ganglion stellate using 8ml of 5% bupivacaine.
Study NCT05078684 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham left ganglion stellate block
Description: Subcutaneous application of 0.5-1ml of 5% bupivacaine to the site of expected LGSB
Study NCT06294444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy
Description: Group A: This group patients will be treated with mCIMT, the forced use of the affected arm by restraining the unaffected arm, with a sling or a hand splint, during dedicated exercise sections or usual ADLs (90% of waking hours).Massed practice (eight hours of exercise) of the affected arm through a shaping method, where shaping involves a commonly operant conditioning method in which a behavioural objective (in this case 'movement') is approached in small steps of progressively increasing difficulty. The participant is rewarded with enthusiastic approval for improvement, but never blamed or punished for failure. This therapy will be given 4hrs daily for 6 weeks. The results will be based upon pre and post evaluation.
Study NCT06294444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: Group B: These patients will be treated with mCIMT and mirror therapy. Children were taught repetitive symmetrical upper limbs exercises: with modelling-clay in each hand to elicit bilateral thumb-finger pinch and grasping. They performed these during a 15-minute daily routine at home with mCIMT (forced use of arm and massed practice 4hrs of exercise of affected arm). This combination of therapy will be given for 6 weeks. The results will be seen through pre and post evaluation.
Study NCT04733222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation training
Description: The treadmill perturbation training will be performed on a computer-controlled treadmill. The perturbation will be induced by fast forward (slip) or backward (trip) accelerations of the treadmill at specific gait cycle timings. The perturbations will be delivered randomly to enhance the unpredictability. A ceiling-mounted body-harness ensures the safety of the participants.~Participants will be assigned to three initial sessions of treadmill slip- and trip-perturbation training on two days separated by a week and a booster-session after six months. On day 1, participants will first undergo a session 1 with 40 slip perturbations and then a session 2 with 40 trip perturbations. On day 2, participants will undergo a session 3 with 20 slip and 20 trip perturbations in random order. The booster-session after six months will be similar to session 3 (20 of each perturbation in random order).
Study NCT04733222 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill walking
Description: Participants allocated to the walking group will walk at a self-selected pace on a computer-controlled treadmill for the same amount of time as the treadmill perturbation training participants.
Study NCT05338866 — intervention group
Intervention type: RADIATION
Intervention: Magnetic resonance guided radiotherapy
Description: Radical radiotherapy boosting for low rectal cancer through magnetic resonance guided radiotherapy linear accelerator.
Study NCT05338866 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: For patients with AJCC stage II and III and age \< 72 years old, Capox ×6→capecitabine×2.~Detailed usage: Oxaliplatin 130mg/m2 (reduced to 100mg/m2 during concurrent chemoradiotherapy), intravenous administration, d1. Capecitabine 1000mg / m2, twice a day, d1-14. Repeated every 3 weeks.~For patients aged ≥ 72 years, or the competent physician judges that the patients cannot tolerate dual drug combined chemotherapy, capecitabine ×8 courses.~For patients with AJCC stage I, capecitabine ×4 courses.
Study NCT04748848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90011
Description: CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle. The dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design.
Study NCT04748848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle with a brief dose ramp-up for Cycle 1 with the dosing of 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Venetoclax should be administered at 400 mg on subsequent days.
Study NCT04748848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine is administered on Days 1 to 7 of each 28-day cycle as an IV infusion or SC injection at 75 mg/m2
Study NCT04748848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle
Study NCT04748848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90011
Description: CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle at the recommended phase to dose of CC-90011 confirmed in dose escalation.
Study NCT05698862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Participants will be required to take a probiotic supplement of Lactobacillus brevis daily (1 capsule 5B CFU/day)
Study NCT05698862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be required to take the placebo maltodextrin daily (1 capsule/day)
Study NCT05665413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: strocking technique, HOT PACK and Ergon instrument
Study NCT06003699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Search Inside Yourself (SIY) program
Description: The present project involves the delivery of the Search Inside Yourself (SIY) program. The SIY Program is organized into 6 thematic modules. The first module introduces mindfulness and emotional intelligence and provides scientific evidence for the benefits of practicing mindfulness. The second module introduces Self-Awareness. The remaining four modules cover other domains based on Daniel Goleman's original framework of Emotional Intelligence: self-management, motivation, empathy, and leadership. Each module is associated with a set of practices, such as focused attention, body scan, journaling, empathic listening, and a Leadership Commitment exercise. The program will be delivered over 4 weeks, with one 3-hour session per week for a total of 12 hours that will take to complete all the modules.
Study NCT06003699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Search Inside Yourself (SIY) program
Description: The present project involves the delivery of the Search Inside Yourself (SIY) program. The SIY Program is organized into 6 thematic modules. The first module introduces mindfulness and emotional intelligence and provides scientific evidence for the benefits of practicing mindfulness. The second module introduces Self-Awareness. The remaining four modules cover other domains based on Daniel Goleman's original framework of Emotional Intelligence: self-management, motivation, empathy, and leadership. Each module is associated with a set of practices, such as focused attention, body scan, journaling, empathic listening, and a Leadership Commitment exercise. The program will be delivered over 4 weeks, with one 3-hour session per week for a total of 12 hours that will take to complete all the modules.
Study NCT05399615 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VOX
Description: Breath biopsy
Study NCT05694962 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-Dose Radiation Therapy
Description: 1.5Gy single treatment of whole-lung radiation therapy
Study NCT06283498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device Morpheus8V
Description: Assigned to be treated using the modified Morpheus8V
Study NCT05256745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP488
Description: Each Azeliragon capsule is 5mg, and is to be taken in the morning with food as indicated in each cohort.
Study NCT05256745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ddAC/ddT
Description: Dose dense doxorubicin plus cyclophosphamide followed by paclitaxel (ddAC/ddT) for 8 cycles, administered per USPI (Unites States Prescribing Information) Label
Study NCT05256745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC
Description: Docetaxel plus cyclophosphamide (TC) for 4-6 cycles, administered per USPI (Unites States Prescribing Information) Label
Study NCT05256745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCHP
Description: Docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP)for 6 cycles, administered per USPI (Unites States Prescribing Information) Label
Study NCT05256745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen that includes ddAC
Description: can include: (1) weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide; (2) weekly carboplatin + paclitaxel followed by dose dense doxorubicin and cyclophosphamide; (3) weekly or dose dense paclitaxel followed by dose dense doxorubicin and cyclophosphamide, administered per USPI (Unites States Prescribing Information) Label
Study NCT05050526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time videoconference-based Exercise program
Description: 12-week exercise program consisting of two weekly 45 minute group-based sessions, remotely supervised by a professional via real-time videoconference. Each session will consist of a warm-up (5-10 min), general strengthening (30 min) and cool-down (5-10 min). Warm-up will include general joint mobility and exercises focused on increasing heart rate. General strengthening will include 4 series of 6 exercises (2 for lower limb, 2 for upper limb and 2 for the trunk) performed with minimal equipment, combining body-weight and elastic-band exercises. Three difficulty levels will be set for each of the exercises, and progression will be made at weeks 5 and 9. Participants will be asked to work in a given rate of perceived exertion (between 3 and 5 in Borg's CR10 scale) and not to reach failure in any of the exercises. Cool-down will include stretching and breathing/relaxing exercises.
Study NCT06254300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: The exercise program will consist of three sessions per week, each lasting 60 minutes. The aerobic exercise will gradually increase the duration throughout the program to 40 minutes and exercise intensity from 30% to 59% of heart rate reserve. The resistance training will include bodyweight functional exercises and resistance exercises using elastic bands. The intensity of resistance exercise will progressively increase according to levels of progressive length and resistance of the elastic bands. The volume of resistance training will start with one set of 8 repetions. It will then gradually increase alongside the program to 2 sets of 12 repetitions. Participants will also be guided to assess their subjective effort using the Borg scale (RPE 12-15).
Study NCT06315114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lighthouse MBT Parenting Program (LPP)
Description: The experimental group is a manualized transdiagnostic mentalization-based parenting intervention (Lighthouse MBT Parenting Program). This is a 12-week parenting group intervention (weekly session of 2 hours) with one preperatory initial individual session (1 hour) before the group commence.